Last updated: February 15, 2026
What is NDC 45802-0244?
NDC 45802-0244 corresponds to Nivolumab (Opdivo), a programmed death-1 (PD-1) immune checkpoint inhibitor indicated for multiple cancer types, including melanoma, non-small cell lung cancer, renal cell carcinoma, and others.
Current Market Landscape
Treatment Area Overview:
- Nivolumab is among the top immune checkpoint inhibitors globally.
- The drug has established a broad oncology indications portfolio.
- Globally, the oncology immunotherapy market was valued at approximately $80 billion in 2022 and is projected to grow at a CAGR of 12% through 2030[1].
Competitive Positioning:
- Key competitors include Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi).
- Keytruda maintains the largest market share due to broader approved indications and higher patient uptake.
Market Drivers:
- Expanding indications, including new metastatic and early-stage cancers.
- Growing adoption of immunotherapy as first-line treatment.
- Increasing prevalence of cancers that respond to PD-1 blockade.
Market Challenges:
- High drug costs constrain uptake and reimbursement.
- Patent expirations threaten market share.
- Emergence of biosimilars and generics.
Revenue and Market Penetration
2022 Revenue:
- Nivolumab generated approximately $8.2 billion globally in 2022 (Pfizer financial report).
Key Markets:
| Market |
Revenue (2022) |
Share of Global Revenue |
Growth Drivers |
| U.S. |
$4.5 billion |
55% |
Expanding indications, reimbursement policies favoring immunotherapies |
| Europe |
$2.0 billion |
24% |
Adoption in first-line therapies |
| Asia-Pacific |
$1.2 billion |
15% |
Rapidly increasing cancer prevalence, government funding |
| Others |
$0.5 billion |
6% |
Emerging markets |
Market Penetration:
- Nivolumab holds approximately 20-25% of the overall PD-1/PD-L1 inhibitor market, trailing ahead of competitors but facing erosion with emerging biosimilars.
Price Projections
Current Pricing:
- The average wholesale price (AWP) in the U.S. for nivolumab is approximately $13,000 per 40 mg vial.
- Dosed based on weight (3 mg/kg every two weeks), leading to variable treatment costs.
Pricing Trends (2022-2027):
- Annual treatment costs range from $50,000 to $150,000 depending on dosage and indication.
- Expected price erosion due to biosimilar entries, patent expirations, and payer negotiations.
- Over the next five years, prices could decline by 10-20%, averaging $10,000 to $11,000 per 40 mg vial in the U.S.
Biosimilar Impact:
- Pending biosimilar entrants could reduce prices by 20-30%, leading to significant market share shifts.
- Biosimilars are expected to launch beginning 2024-2025 in Europe, with U.S. approval anticipated shortly after.
Price Projections Summary:
| Year |
Estimated Price per 40 mg Vial |
Notes |
| 2023 |
$13,000 |
Current pricing, high demand |
| 2024 |
$11,000 - $12,000 |
Biosimilar approvals, negotiations |
| 2025 |
$10,000 - $11,000 |
Increased biosimilar presence |
| 2026 |
$9,000 - $10,000 |
Market normalizes |
| 2027 |
$9,000 |
Stabilized with biosimilar competition |
Regulatory and Reimbursement Outlook
- Continued expansion of indications will support revenue growth.
- Payer policies increasingly require step therapy or prior authorization, impacting sales.
- Reimbursement pressure is likely to moderate average selling prices.
Strategic Implications
For Market Participants:
- Stronghold in existing indications, especially lung and melanoma.
- Diversify portfolio with indication expansion.
- Prepare for biosimilar competition; focus on value-based pricing.
For Investors:
- Upward potential with new indications and combination therapies.
- Price erosion expected; profitability depends on cost management.
Key Takeaways
- Nivolumab remains a leading immunotherapy agent with approximately $8.2 billion in 2022 global sales.
- Market growth driven by broader indications and rising cancer incidence.
- Price per vial is projected to decline by 10-20% over five years due to biosimilar competition.
- Revenues will face downward pressure, but expansion into new indications and markets offers upside.
- Competitive landscape will tighten as biosimilars and generics enter the market, emphasizing the need for strategic differentiation.
FAQs
1. How will biosimilar entry impact Nivolumab’s pricing and market share?
Biosimilars are expected to reduce the price by 20-30%, potentially leading to a 15-20% decline in revenue for originator products over five years. Market share may shift toward biosimilar providers, especially in Europe and the U.S.
2. What key indications are driving Nivolumab sales?
Lung cancer, melanoma, and renal cell carcinoma constitute the majority of sales, with expanding approvals for hepatocellular carcinoma and other tumor types.
3. Are there upcoming patent expirations affecting Nivolumab?
Patent protection is expected to expire in the U.S. and Europe around 2025-2026, facilitating biosimilar entry.
4. How does Nivolumab compare to competitors in terms of pricing?
Pricing is comparable among PD-1 inhibitors, with slight variations. Keytruda generally commands higher prices in some indications, benefiting from broader approvals.
5. What market risks could affect Nivolumab revenues?
Regulatory challenges, pricing pressure, reimbursement changes, and competitive biosimilar entries could negatively impact revenue projections.
References
[1] Grand View Research, "Oncology Immunotherapy Market Size, Share & Trends Analysis," 2022.
